RA
CMPX icon

Royce & Associates’s Compass Therapeutics CMPX Stock Holding History

Royce & Associates’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.57M Buy
1,619,798
+1,333,810
+466% +$7.7M 0.08% 372
2025
Q4 		$1.54M Buy
+285,988
New +$1.32M 0.02% 628

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Royce & Associates's CMPX Position: Q1 2026 in Review

Royce & Associates increased its Compass Therapeutics (CMPX) stake by 466% in Q1 2026, buying an estimated $7.7M and bringing the position to 1,619,798 shares worth $8.57M. The position accounts for 0.08% of the portfolio, ranked #372.

Royce & Associates first reported a position in CMPX in Q4 2025 and has held it in 2 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Royce & Associates held 1,619,798 shares of Compass Therapeutics worth $8.57M as of Q1 2026.
  • Royce & Associates bought 1,333,810 Compass Therapeutics shares in Q1 2026, an estimated $7.7M.
  • Compass Therapeutics made up 0.08% of Royce & Associates's portfolio in Q1 2026, its #372 holding.
  • Royce & Associates first reported a position in Compass Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Royce & Associates's 13F filing for Q1 2026, filed 12 May 2026.